Ownership history in Prosight Management, LP Β· 14 quarters on record
This page tracks every 13F SEC filing in which Prosight Management, LP reported a position in ADC THERAPEUTICS SA (ADCT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Prosight Management, LP outperformed the S&P 500 by +29.8% annually on this ADCT position. Timing score: 46% (6/13 decisions correct). Average cost basis: $2.64. Maximum drawdown during holding period: β81.3%.
π₯ Exceptional β beat the S&P 500 by 29.8% per year on this position.
13 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
6 of 13 add/trim decisions correct
Best entry: $1.41 (2025 Q1) Β· Worst: $4.82 (2022 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
11 adds Β· 3 trims. Bought during 6 of 8 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Prosight Management, LP has been actively increasing its ADCT allocation β a bullish signal from insiders.
Currently 6.18% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size